Navigation Links
Fox Chase researchers report that naproxen reduces tumors in a mouse model of colon cancer
Date:4/6/2011

ORLANDO, FL (April 6, 2011) Numerous studies show that non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of colon cancer. However, animal studies testing the NSAID naproxen or its derivative, NO-naproxen, have focused primarily on chemically-induced tumor formation. Now, researchers at Fox Chase Cancer Center find that naproxen and NO-naproxen reduce tumor formation in a strain of mutant mice that spontaneously develop colon tumors. The data also suggest that naproxen blocks a gatekeeper step that initiates tumor formation.

Margie Clapper, PhD, Co-Leader of the Cancer Prevention and Control Program at Fox Chase, will present the data in a late-breaking abstract session at the AACR 102nd Annual Meeting 2011 on Wednesday, April 6.

"There is a major effect on the very small lesions, about a 90% reduction in the mutant mice treated with naproxen compared with control animals," says Clapper. "That tells us this drug may be very appropriate for intervening early in people, far in advance of the development of large tumors. We might be able to have a significant impact on the very early and small lesions, thus reducing the morbidity associated with the disease."

Scientists have shown previously that both naproxen and NO-naproxen kill colon cancer cells in culture, with NO-naproxen appearing to be more powerful than naproxen. In the current study, the team fed mice genetically predisposed to spontaneously develop colon tumors either regular food or food supplemented with high- or low-dose naproxen or high- or low-dose NO-naproxen. After 45 days, they found that mice fed low-dose naproxen had 70.3% fewer small tumors than the control animals and mice fed low-dose NO-naproxen had 64.0% fewer tumors than control animals. Moreover, a 89.3% reduction in very small tumors, known as microadenomas, was observed when mice were fed high-dose naproxen.

Although Clapper and first author Wen-Chi Chang, PhD, Assistant Research Professor at Fox Chase, had expected that NO-naproxen would be a more powerful chemopreventive agent based on cell culture data, the current study indicates this is not the case in animals.

Clapper says their results, which favor naproxen, fit well with a recent decision by the U.S. Food and Drug Administration (FDA). Scientists had developed NO-naproxen with the goal of reducing gastrointestinal toxicity associated with regular use of NSAIDs. The FDA, however, declined to approve NO-naproxen saying there was not enough evidence that it was less toxic than the older drug. "Our data are highly supportive of using what is already on the market, and FDA approved for arthritis, for the prevention of cancer," Clapper says.

Chang says a key aspect of the new data is naproxen's ability to block a very early step in colon cancer formation. "If we can identify the exact mechanism that naproxen uses to block tumor formation, then, in the future, we can work with chemists to design a compound that hits that pathway, without the broad spectrum of effects and side effects seen with NSAIDs," Chang says.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Hollywood-Style Liposuction Comes to DC: Chevy Chase Smartlipo Brings Revolutionary Laser-Assisted Liposuction to DC Metro Area
2. Torchmark Corporation Declares Dividend and Resumes Stock Repurchases
3. International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc.
4. Grand Opening of LIFE Ionizer Australia Launches with a Free Ionizer Upgrade with Purchase of Alkaline Water Ionizer from LIFE Ionizer Australia
5. A New Twist On Convert to Purchase
6. Ensemble Healthcare Properties Purchases North Valley Medical Plaza
7. ARI Purchases Intercytex Assets
8. CapSite™ Provides Detailed Transparency on Healthcare Technology Purchases
9. Ivory Homes Plans Ahead for the April 30th Home Buyer Tax Credit Deadline with 100 New Homes Ready for Quick Purchase
10. R-Biopharm Group Purchases a Majority Ownership in Trilogy Lab, Expanding US Operations
11. Fox Chase clinical trial tests first of its kind antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ATLANTA, Ga. (PRWEB) , ... July 27, 2017 , ... ... Man native Sam Brand to the men’s pro squad as a stagiaire for the ... to make his professional debut on July 31st at the Tour of Utah. , ...
(Date:7/26/2017)... ... 26, 2017 , ... Written By: Ashley D. Beall, MD, ... drug therapy for patients living with relapsing and primary multiple sclerosis that can ... targeted therapy that has been proven to significantly reduce signs of disease activity ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we thought there could ... Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK BRACKETS ... doing so, it offers an effective alternative to traditional braces. As a result, it ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with Six ... schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients ... will bring more Six Month Smiles patients to their providers.” , Each month, over ...
(Date:7/26/2017)... Wheaton, IL (PRWEB) , ... July 26, 2017 , ... Wendy M. Musielak, ... Cores LLP, was elected as DuPage County Bar Association’s third Vice President earlier this year. ... succeeding to the office of the second Vice President, in accordance with the organization’s by-laws. ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... know that PhRMA member companies invested $65.5 billion in research and ... generics and the supply chain account for 14 percent of total ... (7 percent)? Or that the United States ... high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts for 1 ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
Breaking Medicine Technology: